Oral Oncology
Volume 46, Issue 3 , Pages 135-145 , March 2010

Kaposi’s sarcoma of the head and neck: A review

  • Velia Ramírez-Amador

      Affiliations

    • Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Villa Quietud, México D.F., Mexico
    • Corresponding Author InformationCorresponding author. Address: Camino Sta. Teresa 277-9, Col. Parques del Pedergal, Mexico D.F. 14010, Mexico. Tel.: +52 (55) 5606 1781; fax: +52 (55) 5483 7206.
    • Tel.: +52 (55) 5483 7206.
    • ,
  • Gabriela Anaya-Saavedra

      Affiliations

    • Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Villa Quietud, México D.F., Mexico
    • Tel.: +52 (55) 5483 7206.
    • ,
  • Guillermo Martínez-Mata

      Affiliations

    • Facultad de Odontología, Universidad Autónoma de Chihuahua, Av. Escorza No. 900, Zona Centro CP 3100, Chihuahua, Mexico
    • Tel.: +52 (614) 439 1500.

Received 20 October 2009 ,Revised 17 December 2009 ,Accepted 18 December 2009.

References 

  1. Ramírez-Amador V, Martínez-Mata G, González-Ramírez I, Anaya-Saavedra G, de Almeida OP. Clinical, histological and immunohistochemical findings in oral Kaposi’s sarcoma in a series of Mexican AIDS patients. Comparative study. J Oral Pathol Med. 2009;38(4):328–333
  2. Feller L, Wood NH, Lemmer J. HIV-associated Kaposi sarcoma: pathogenic mechanisms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(4):521–529
  3. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48(1):3–12
  4. Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008;59(2):179–206
  5. Szajerka T, Jablecki J. Kaposi’s sarcoma revisited. AIDS Rev. 2007;9(4):230–236
  6. Lanternier F, Lebbé C, Schartz N, Farhi D, Marcelin AG, Kérob D, et al. Kaposi’s sarcoma in HIV-negative men having sex with men. AIDS. 2008;22(10):1163–1168
  7. Sissolak G, Mayaud P. AIDS-related Kaposi’s sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health. 2005;10(10):981–992
  8. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993–1995. Int J Cancer. 2000;85(1):54–59
  9. Bagni R, Whitby D. Kaposi’s sarcoma-associated herpesvirus transmission and primary infection. Curr Opin HIVAIDS. 2009;4(1):22–26
  10. Pica F, Volpi A. Transmission of human herpesvirus 8: an update. Curr Opin Infect Dis. 2007;20(2):152–156
  11. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS. 2003;17(12):1717–1730
  12. Duprez R, Lacoste V, Brière J, Couppié P, Frances C, Sainte-Marie D, et al. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst. 2007;99(14):1086–1094
  13. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865–1869
  14. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi’s sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol. 2003;77(7):4205–4220
  15. Dubina M, Goldenberg G. Positive staining of tumor-stage Kaposi sarcoma with lymphatic marker D2-40. J Am Acad Dermatol. 2009;61(2):276–280
  16. Long E, Ilie M, Hofman V, Havet K, Selva E, Butori C, et al. LANA-1, Bcl-2, Mcl-1 and HIF-1alpha protein expression in HIV-associated Kaposi sarcoma. Virchows Arch. 2009;455(2):159–170
  17. Montaner S. Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi’s sarcoma. Cell Cycle. 2007;6(4):438–443
  18. Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, et al. Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 2002;76(16):8383–8399
  19. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi’s sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol. 1999;163(4):1929–1935
  20. Stürzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G, et al. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst. 1999;91(20):1725–1733
  21. Arav-Boger R. Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes. 2009;38(2):195–203
  22. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8(2):167–176
  23. Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol. 2008;68(3):242–249
  24. Dal Maso L, Polesel J, Ascoli V, Zambon P, Budroni M, Ferretti S, et al. Cancer and AIDS registry linkage study. Classic Kaposi’s sarcoma in Italy, 1985–1998. Br J Cancer. 2005;92(1):188–193
  25. Vitale F, Briffa DV, Whitby D, Maida I, Grochowska A, Levin A, et al. Kaposi’s sarcoma herpes virus and Kaposi’s sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer. 2001;91(4):588–591
  26. Iscovich J, Boffetta P, Winkelmann R, Brennan P, Azizi E. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12(15):2067–2072
  27. Iscovich J, Boffetta P, Brennan P. Classic Kaposi’s sarcoma in Arabs living in Israel, 1970–1993: a population-based incidence study. Int J Cancer. 1998;77(3):319–321
  28. Grulich AE, Beral V, Swerdlow AJ. Kaposi’s sarcoma in England and Wales before the AIDS epidemic. Br J Cancer. 1992;66(6):1135–1137
  29. Mosam A, Carrara H, Shaik F, Uldrick T, Berkman A, Aboobaker J, et al. Increasing incidence of Kaposi’s sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983–2006). Int J STD AIDS. 2009;20(8):553–556
  30. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82(9):1585–1592
  31. Parkin DM, Vizcaino AP, Skinner ME, Ndhlovu A. Cancer patterns and risk factors in the African population of southwestern Zimbabwe, 1963–1977. Cancer Epidemiol Biomarkers Prev. 1994;3(7):537–547
  32. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54(1):26–36
  33. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans–burden, distribution, and trends. Lancet Oncol. 2008;9(7):683–692
  34. Chokunonga E, Levy LM, Bassett MT, Borok MZ, Mauchaza BG, Chirenje MZ. Aids and cancer in Africa the evolving epidemic in Zimbabwe. AIDS. 1999;13(18):2583–2588
  35. Ziegler JL, Katongole-Mbidde E. Kaposi’s sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer. 1996;65(2):200–203
  36. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. Cancer. 2004;100(12):2644–2654
  37. Serraino D, Angeletti C, Carrieri MP, Longo B, Piche M, Piselli P, et al. for the Immunesuppression and Cancer Study Group. Kaposi’s sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation. 2005;80(12):1699–1704
  38. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–3044
  39. Atkinson JO, Biggar RJ, Goedert JJ, Engels EA. The incidence of Kaposi sarcoma among injection drug users with AIDS in the United States. J Acquir Immune Defic Syndr. 2004;37(2):1282–1287
  40. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94(16):1204–1210
  41. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi’s sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24(3):270–274
  42. Mbulaiteye SM, Engels EA. Kaposi’s sarcoma risk among transplant recipients in the United States (1993–2003). Int J Cancer. 2006;119(11):2685–2691
  43. Tessari G, Naldi L, Boschiero L, Cordiano C, Piaserico S, Fortina AB, et al. Incidence and clinical predictors of Kaposi’s sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol. 2006;16(5):553–557
  44. Simonart T. Role of environmental factors in the pathogenesis of classic and African-endemic Kaposi sarcoma. Cancer Lett. 2006;244(1):1–7
  45. Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. Int J Infect Dis. 2005;9(5):239–250
  46. Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78(11):1521–1528
  47. Chintu C, Athale UH, Patil PS. Childhood cancers in Zambia before and after the HIV epidemic. Arch Dis Child. 1995;73(2):100–104
  48. Dedicoat M, Newton R. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer. 2003;88(1):1–3
  49. Sinfield RL, Molyneux EM, Banda K, Borgstein E, Broadhead R, Hesseling P, et al. Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998–2003. Pediatr Blood Cancer. 2007;48(5):515–520
  50. Athale UH, Patil PS, Chintu C, Elem B. Influence of HIV epidemic on the incidence of Kaposi’s sarcoma in Zambian children. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(1):96–100
  51. Antman K, Chang Y. Kaposi’s sarcoma. New Engl J Med. 2000;342(14):1027–1038
  52. Mwanda OW, Fu P, Collea R, Whalen C, Remick SC. Kaposi’s sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann Trop Med Parasitol. 2005;99(1):81–91
  53. Olweny CL, Borok M, Gudza I, Clinch J, Cheang M, Kiire CF, et al. Treatment of AIDS-associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113(4):632–639
  54. Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. 2005;19(10):635–644
  55. Crane HM, Deubner H, Huang JC, Swanson PE, Harrington RD. Fatal Kaposi’s sarcoma-associated immune reconstitution following HAART initiation. Int J STD AIDS. 2005;16(1):80–83
  56. Papagatsia Z, Jones J, Morgan P, Tappuni AR. Oral Kaposi sarcoma: a case of immune reconstitution inflammatory syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(1):70–75
  57. Ramírez-Amador VA, Espinosa E, González-Ramírez I, Anaya-Saavedra G, Ormsby CE, Reyes-Terán G. Identification of oral candidosis, hairy leukoplakia and recurrent oral ulcers as distinct cases of immune reconstitution inflammatory syndrome. Int J STD AIDS. 2009;20(4):259–261
  58. Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J Periodontol. 2008;79(2):362–368
  59. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23(22):5224–5228
  60. Buonaguro FM, Tomesello ML, Buonaguro L, Satriano RA, Ruocco E, Castello G, et al. Kaposi’s sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol. 2003;17(2):138–154
  61. Mendez JC, Paya CV. Kaposi’s sarcoma and transplantation. Herpes. 2000;7:1
  62. Lebbé C, Legendre C, Francès C. Kaposi sarcoma in transplantation. Transplant Rev (Orlando). 2008;22(4):252–261
  63. Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, et al. Risk of Kaposi’s sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi’s sarcoma patients. Blood. 1997;90(7):2826–2829
  64. National Cancer Institute. Kaposi sarcoma treatment. Health Professional Version. <http://www.cancer.gov.cancertopics/pdq/treatment/kaposis/healthprofesional/allpages> [accessed 11.10.09].
  65. Piselli P, Busnach G, Citterio F, Frigerio M, Arbustini E, Burra P, et al. Immunosuppression and Cancer Study Group. Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4767 recipients in Italy, 1970–2006. Transplant Proc. 2009;41(4):1227–1230
  66. Ganem D. KSHV infection and the pathogenesis of Kaposi’s sarcoma. Annu Rev Pathol. 2006;1:273–296
  67. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. Int J Cancer. 1996;65(1):25–28
  68. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet. 1995;346(8978):799–802
  69. Lefrère JJ, Meyohas MC, Mariotti M, Meynard JL, Thauvin M, Frottier J. Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi’s sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. J Infect Dis. 1996;174(2):283–287
  70. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. New Engl J Med. 1996;335(4):233–241
  71. Anderson LA, Lauria C, Romano N, Brown EE, Whitby D, Graubard BI, et al. Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3435–3443
  72. Mancuso R, Biffi R, Valli M, Bellinvia M, Tourlaki A, Ferrucci S, et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi’s sarcoma. J Med Virol. 2008;80(12):2153–2160
  73. Ramos-da-Silva S, Elgui-de-Oliveira D, Borges L, Bacchi CE. Kaposi’s sarcoma-associated herpesvirus infection and Kaposi’s sarcoma in Brazil. Braz J Med Biol Res. 2006;39(5):573–580
  74. Guttman-Yassky E, Dubnov J, Kra-Oz Z, Friedman-Birnbaum R, Silbermann M, Barchana M, et al. Classic Kaposi sarcoma. Which KSHV-seropositive individuals are at risk? Cancer. 2006;106(2):413–419
  75. Guttman-Yassky E, Kra-Oz Z, Dubnov J, Friedman-Birnbaum R, Segal I, Zaltzman N, et al. Infection with Kaposi’s sarcoma-associated herpesvirus among families of patients with classic Kaposi’s sarcoma. Arch Dermatol. 2005;141(11):1429–1434
  76. Hbid O, Belloul L, Fajali N, Ismaili N, Duprez R, Tanguy M, et al. Kaposi’s sarcoma in Morocco: a pathological study with immunostaining for human herpesvirus-8 LNA-1. Pathology. 2005;37(4):288–295
  77. Dilnur P, Katano H, Wang ZH, Osakabe Y, Kudo M, Sata T, et al. Classic type of Kaposi’s sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int. 2001;51(11):845–852
  78. Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, Masala MV, et al. High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi’s sarcoma from Sardinia. J Infect Dis. 1998;177(6):1715–1718
  79. Chatlynne LG, Lapps W, Handy M, Huang YQ, Masood R, Hamilton AS, et al. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immunodeficiency syndrome patients, and Kaposi’s sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood. 1998;92(1):53–58
  80. Cathomas G, McGandy CE, Terracciano LM, Itin PH, De Rosa G, Gudat F. Detection of herpesvirus-like DNA by nested PCR on archival skin biopsy specimens of various forms of Kaposi sarcoma. J Clin Pathol. 1996;49(8):631–633
  81. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, et al. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348(9035):1133–1138
  82. Wamburu G, Masenga EJ, Moshi EZ, Schmid-Grendelmeier P, Kempf W, Orfanos CE. HIV-associated and non-HIV associated types of Kaposi’s sarcoma in an African population in Tanzania. Status of immune suppression and HHV-8 seroprevalence. Eur J Dermatol. 2006;16(6):677–682
  83. Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol. 2003;27(12):1546–1550
  84. Fouchard N, Lacoste V, Couppie P, Develoux M, Mauclere P, Michel P, et al. Detection and genetic polymorphism of human herpes virus type 8 in endemic or epidemic Kaposi’s sarcoma from West and Central Africa, and South America. Int J Cancer. 2000;85(2):166–170
  85. Kennedy MM, Lucas SB, Jones RR, Howells DD, Picton SJ, Hanks EE, et al. HHV8 and Kaposi’s sarcoma: a time cohort study. Mol Pathol. 1997;50(2):96–100
  86. Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi’s sarcoma in Africa. J Gen Virol. 1997;78(Pt 4):847–855
  87. Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, Katongole-Mbidde E, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One. 2009;4(1):e4222
  88. Kumar N, McLean K, Inoue N, Moles DR, Scully C, Porter SR, et al. Human herpesvirus 8 genoprevalence in populations at disparate risks of Kaposi’s sarcoma. J Med Virol. 2007;79(1):52–59
  89. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, Radford KW, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi’s sarcoma. AIDS. 2007;21(12):1541–1545
  90. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. New Engl J Med. 1999;340(24):1863–1871
  91. Zhu L, Wang R, Sweat A, Goldstein E, Horvat R, Chandran B. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology. 1999;256(2):381–392
  92. Rezza G, Lennette ET, Giuliani M, Pezzotti P, Caprilli F, Monini P, et al. Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. Int J Cancer. 1998;77(3):361–365
  93. Lin SF, Sun R, Heston L, Gradoville L, Shedd D, Haglund K, et al. Identification, expression, and immunogenicity of Kaposi’s sarcoma-associated herpesvirus-encoded small viral capsid antigen. J Virol. 1997;71(4):3069–3076
  94. Zhang X, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo M, et al. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis. 1998;178(5):1488–1491
  95. Al-Otaibi LM, Al-Sulaiman MH, Teo CG, Porter SR. Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009;24(2):109–115
  96. Zavos G, Bokos J, Papaconstantinou I, Boletis J, Gazouli M, Kakisis J, et al. Clinicopathological aspects of 18 Kaposi’s sarcoma among 1055 Greek renal transplant recipients. Artif Organs. 2004;28(6):595–599
  97. Briz M, Alonso-Pulpon L, Crespo-Leiro MG, Exposito C, Almagro M, Busto MJ, et al. Detection of herpesvirus-like sequences in Kaposi’s sarcoma from heart transplant recipients. J Heart Lung Transplant. 1998;17(3):288–293
  98. Rady PL, Hodak E, Yen A, Memar O, Trattner A, Feinmesser M, et al. Detection of human herpesvirus-8 DNA in Kaposi’s sarcomas from iatrogenically immunosuppressed patients. J Am Acad Dermatol. 1998;38(3):429–437
  99. Alkan S, Karcher DS, Ortiz A, Khalil S, Akhtar M, Ali MA. Human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus in organ transplant patients with immunosuppression. Br J Haemato. 1997;96(2):412–414
  100. Giuliani M, Cordiali-Fei P, Castilletti C, Di Carlo A, Palamara G, Boros S, et al. Incidence of human herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections. BMC Infect Dis. 2007;7:143
  101. Martró E, Esteve A, Schulz TF, Sheldon J, Gambús G, Muñoz R, et al. For the Euro-Shaks study group. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007;120(5):1129–1135
  102. Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, Norhanom AW, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer. 1999;81(5):893–897
  103. Bélec L, Cancré N, Hallouin MC, Morvan J, Si Mohamed A, Grésenguet G. High prevalence in Central Africa of blood donors who are potentially infectious for human herpesvirus 8. Transfusion. 1998;38(8):771–775
  104. He J, Bhat G, Kankasa C, Chintu C, Mitchell C, Duan W, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi’s sarcoma (KS) and mother–child pairs with KS. J Infect Dis. 1998;178(6):1787–1790
  105. Olsen SJ, Chang Y, Moore PS, Biggar RJ, Melbye M. Increasing Kaposi’s sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi’s sarcoma endemic region, Zambia in 1985. AIDS. 1998;12(14):1921–1925
  106. de Souza VA, Sumita LM, Nascimento MC, Oliveira J, Mascheretti M, Quiroga M, et al. Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region. J Infect Dis. 2007;196(6):844–852
  107. Batista MD, Ferreira S, Sauer MM, Tomiyama H, Giret MT, Pannuti CS, et al. High human herpesvirus 8 (HHV-8) prevalence, clinical correlates and high incidence among recently HIV-1-infected subjects in Sao Paulo, Brazil. PLoS One. 2009;4(5):e5613
  108. Fu B, Sun F, Li B, Yang L, Zeng Y, Sun X, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus and risk factors in Xinjiang, China. J Med Virol. 2009;81(8):1422–1431
  109. Guanira JV, Casper C, Lama JR, Morrow R, Montano SM, Caballero P, et al. For the Peruvian HIV Sentinel Surveillance Working Group. Prevalence and correlates of human herpesvirus 8 infection among Peruvian men who have sex with men. J Acquir Immune Defic Syndr. 2008;49(5):557–562
  110. Widmer IC, Erb P, Grob H, Itin P, Baumann M, Stalder A, et al. Human herpesvirus 8 oral shedding in HIV-infected men with and without Kaposi sarcoma. J Acquir Immune Defic Syndr. 2006;42(4):420–425
  111. Cannon MJ, Dollard SC, Smith DK, Klein RS, Schuman P, Rich JD, et al. HIV Epidemiology Research Study Group. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. New Engl J Med. 2001;344(9):637–643
  112. Perna AM, Bonura F, Vitale F, Viviano E, Di Benedetto MA, Ajello F, et al. Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily. Int J Epidemiol. 2000;29(1):175–179
  113. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet. 1996;348(9031):858–861
  114. Casper C, Wald A, Pauk J, Tabet SR, Corey L, Celum CL. Correlates of prevalent and incident Kaposi’s sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis. 2002;185(7):990–993
  115. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. New Engl J Med. 1998;338(14):948–954
  116. Casper C, Carrell D, Miller KG, Judson FD, Meier AS, Pauk JS, et al. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect. 2006;82(3):229–235
  117. Grulich AE, Cunningham P, Munier ML, Prestage G, Amin J, Ringland C, et al. Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. Sex Health. 2005;2(1):13–18
  118. Dukers NH, Renwick N, Prins M, Geskus RB, Schulz TF, Weverling GJ, et al. Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol. 2000;151(3):213–224
  119. Grulich AE, Kaldor JM, Hendry O, Luo K, Bodsworth NJ, Cooper DA. Risk of Kaposi’s sarcoma and oroanal sexual contact. Am J Epidemiol. 1997;145(8):673–679
  120. Baeten JM, Chohan BH, Lavreys L, Rakwar JP, Ashley R, Richardson BA, et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. AIDS. 2002;16(15):2073–2078
  121. McDonald AC, Ragin CC, Jenkins FJ, Weissfeld J, Wilson J, Wheeler VW, et al. Human herpesvirus 8 seroprevalence among Tobago women and the role of sexual lifestyle behavior. J Med Virol. 2009;81(2):264–270
  122. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187–194
  123. Smith NA, Sabin CA, Gopal R, Bourboulia D, Labbet W, Boshoff C, et al. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis. 1999;180(3):600–606
  124. Malope BI, MacPhail P, Mbisa G, MacPhail C, Stein L, Ratshikhopha EM, et al. No evidence of sexual transmission of Kaposi’s sarcoma herpes virus in a heterosexual South African population. AIDS. 2008;22(4):519–526
  125. de Sanjose S, Mbisa G, Perez-Alvarez S, Benavente Y, Sukvirach S, Hieu NT, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis. 2009;199(10):1449–1456
  126. Hladik W, Dollard SC, Downing RG, Kataaha P, Pellett PE, Karon JM, et al. Kaposi’s sarcoma in Uganda: risk factors for human herpesvirus 8 infection among blood donors. J Acquir Immune Defic Syndr. 2003;33(2):206–210
  127. Gandhi M, Koelle DM, Ameli N, Bacchetti P, Greenspan JS, Navazesh M, et al. Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count. J Dent Res. 2004;83(8):639–643
  128. Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol. 1997;71(9):7083–7087
  129. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, et al. Mucosal shedding of human herpesvirus 8 in men. New Engl J Med. 2000;343(19):1369–1377
  130. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 1997;176(1):94–102
  131. Gessain A, Mauclère P, van Beveren M, Plancoulaine S, Ayouba A, Essame-Oyono JL, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer. 1999;81(2):189–192
  132. Plancoulaine S, Abel L, van Beveren M, Trégouët DA, Joubert M, Tortevoye P, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000;356(9235):1062–1065
  133. Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA. 2002;287(10):1295–1300
  134. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least two patterns of KSHV transmission. J Infect Dis. 2009;200(3):430–438
  135. Taylor MM, Chohan B, Lavreys L, Hassan W, Huang ML, Corey L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis. 2004;190(3):484–488
  136. Mbulaiteye SM, Pfeiffer RM, Engels EA, Marshall V, Bakaki PM, Owor AM, et al. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis. 2004;190(8):1382–1386
  137. Minhas V, Crabtree KL, Chao A, M’soka TJ, Kankasa C, Bulterys M, et al. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol. 2008;168(3):311–320
  138. Malope BI, Pfeiffer RM, Mbisa G, Stein L, Ratshikhopha EM, O’Connell DL, et al. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr. 2007;44(3):351–355
  139. Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis. 2004;190(6):1068–1075
  140. Mayama S, Cuevas LE, Sheldon J, Omar OH, Smith DH, Okong P, et al. Prevalence and transmission of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer. 1998;77(6):817–820
  141. Beyari MM, Hodgson TA, Cook RD, Kondowe W, Molyneux EM, Scully CM, et al. Multiple human herpesvirus-8 infection. J Infect Dis. 2003;188(5):678–689
  142. Cook RD, Hodgson TA, Waugh AC, Molyneux EM, Borgstein E, Sherry A, et al. Mixed patterns of transmission of human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) in Malawian families. J Gen Virol. 2002;83(Pt 7):1613–1619
  143. Triantos D, Horefti E, Paximadi E, Kyriakopoulou Z, Karakassiliotis G, Papanastasiou K, et al. Presence of human herpes virus-8 in saliva and non-lesional oral mucosa in HIV-infected and oncologic immunocompromised patients. Oral Microbiol Immunol. 2004;19(3):201–204
  144. Casper C, Krantz E, Selke S, Kuntz SR, Wang J, Huang ML, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis. 2007;195(1):30–36
  145. Duus KM, Lentchitsky V, Wagenaar T, Grose C, Webster-Cyriaque J. Wild-type Kaposi’s sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J Virol. 2004;78(8):4074–4084
  146. Webster-Cyriaque J, Duus K, Cooper C, Duncan M. Oral EBV and KSHV infection in HIV. Adv Dent Res. 2006;19(1):91–95
  147. Wood NH, Feller L. The malignant potential of HIV-associated Kaposi sarcoma. Cancer Cell Int. 2008;8:14
  148. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Stürzl M, Monini P. Biology of Kaposi’s sarcoma. Eur J Cancer. 2001;37(10):1251–1269
  149. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, et al. Monoclonal origin of multicentric Kaposi’s sarcoma lesions. New Engl J Med. 1997;336(14):988–993
  150. Rabkin CS, Bedi G, Musaba E, Sunkutu R, Mwansa N, Sidransky D, et al. AIDS-related Kaposi’s sarcoma is a clonal neoplasm. Clin Cancer Res. 1995;1(3):257–260
  151. Delabesse E, Oksenhendler E, Lebbé C, Vérola O, Varet B, Turhan AG. Molecular analysis of clonality in Kaposi’s sarcoma. J Clin Pathol. 1997;50(8):664–668
  152. Gill PS, Tsai YC, Rao AP, Spruck CH, Zheng T, Harrington WA, et al. Evidence for multiclonality in multicentric Kaposi’s sarcoma. Proc Natl Acad Sci USA. 1998;95(14):8257–8261
  153. Judde JG, Lacoste V, Brière J, Kassa-Kelembho E, Clyti E, Couppié P, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi’s sarcoma and other diseases. J Natl Cancer Inst. 2000;92(9):729–736
  154. Dictor M, Rambech E, Way D, Witte M, Bendsöe N. Human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) DNA in Kaposi’s sarcoma lesions, AIDS Kaposi’s sarcoma cell lines, endothelial Kaposi’s sarcoma simulators, and the skin of immunosuppressed patients. Am J Pathol. 1996;148(6):2009–2016
  155. Huang YQ, Li JJ, Zhang WG, Feiner D, Friedman-Kien AE. Transcription of human herpesvirus-like agent (HHV-8) in Kaposi’s sarcoma. J Clin Invest. 1996;97(12):2803–2806
  156. Jin YT, Tsai ST, Yan JJ, Chen FF, Lee WY, Li WY, et al. Presence of human herpesvirus-like DNA sequence in oral Kaposi’s sarcoma. A preliminary PCR study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(4):442–444
  157. Huang YQ, Li JJ, Kaplan MH, Poiesz B, Katabira E, Zhang WC, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi’s sarcoma. Lancet. 1995;345(8952):759–761
  158. Feller L, Lemmer J. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. Infect Agent Cancer. 2008;3:1
  159. Horenstein MG, Moontasri NJ, Cesarman E. The pathobiology of Kaposi’s sarcoma: advances since the onset of the AIDS epidemic. J Cutan Pathol. 2008;35(2):40–44
  160. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2009. doi:10.1016/j.canlet.2009.07.004.
  161. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3(1):23–36
  162. Verma SC, Robertson ES. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett. 2003;222(2):155–163
  163. Schwartz RA. Kaposi’s sarcoma: an update. J Surg Oncol. 2004;87(3):146–151
  164. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88(3):500–517
  165. Lamovec J, Knuutila S. Kaposi Sarcoma. In:  Fletcher CDM,  Unni KK,  Mertens F editor. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002;p. 170–172
  166. Regezi JA, MacPhail LA, Daniels TE, Greenspan JS, Greenspan D, Dodd CL, et al Oral Kaposi’s sarcoma: a 10-year retrospective histopathologic study. J Oral Pathol Med. 1993;22(7):292–297
  167. Ramírez-Amador V, González M, de la Rosa E, Esquivel L, Volkow P, Ochoa FJ, et al. Oral findings in Mexican AIDS patients with cancer. J Oral Pathol Med. 1993;22(2):87–91
  168. Mohanna S, Bravo F, Ferrufino JC, Sanchez J, Gotuzzo E. Classic Kaposi’s sarcoma presenting in the oral cavity of two HIV-negative Quechua patients. Med Oral Patol Oral Cir Bucal. 2007;12(5):E365–368
  169. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2(5):281–292
  170. Sissolak G, Mayaud P. AIDS-related Kaposi’s sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health. 2005;10(10):981–992
  171. Taylor JF, Templeton AC, Vogel CL, Ziegler JL, Kyalwazi SK. Kaposi’s sarcoma in Uganda: a clinico-pathological study. Int J Cancer. 1971;8(1):122–135
  172. Duman S, Töz H, Asçi G, Alper S, Ozkahya M, Unal I, et al. Successful treatment of post-transplant Kaposi’s sarcoma by reduction of immunosuppression. Nephrol Dial Transplant. 2002;17(5):892–896
  173. Patrikidou A, Vahtsevanos K, Charalambidou M, Valeri RM, Xirou P, Antoniades K. Kaposi’s sarcoma in the head and neck area. Head Neck. 2009;31(2):260–268
  174. Jindal JR, Campbell BH, Ward TO, Almagro US. Kaposi’s sarcoma of the oral cavity in a non-AIDS patient: case report and review of the literature. Head Neck. 1995;17(1):64–68
  175. Pagani D, Bellinvia M, Capaccio P, Scoppio B, Brambilla L, Pignataro L. An unusual cause of a parotid mass in an immunocompetent host: classic Kaposi’s sarcoma. Tumori. 2009;95(2):248–250
  176. Cottoni F, Masala MV, Piras P, Montesu MA, Cerimele D. Mucosal involvement in classic Kaposi’s sarcoma. Br J Dermatol. 2003;148(6):1273–1274
  177. Reis-Filho JS, Souto-Moura C, Lopes JM. Classic Kaposi’s sarcoma of the tongue: case report with emphasis on the differential diagnosis. J Oral Maxillofac Surg. 2002;60(8):951–954
  178. Puxeddu R, Parodo G, Locci F, Puxeddu I, Manconi PE, Ferreli C. Parotid mass as an early sign of Kaposi’s sarcoma associated with human herpesvirus 8 infection. J Laryngol Otol. 2002;116(6):470–473
  179. Mwakigonja AR, Pak F, Pyakurel P, Mosha IJ, Urassa WK, Kaaya EE, et al. Oral Kaposi’s sarcoma in Tanzania: presentation, immunopathology and human herpesvirus-8 association. Oncol Rep. 2007;17(6):1291–1299
  180. Choussy O, Van Haverbeke C, Babin E, Francois A, Duval-Modeste AB, Dehesdin D. Unusual presentation of oropharyngeal Kaposi’s sarcoma. Head Neck. 2008;30(3):411–415
  181. Pantanowitz L, Dezube BJ. Kaposi sarcoma in unusual locations. BMC Cancer. 2008;8:190
  182. Steele NP, Sampogna D, Sessions RB. Kaposi’s sarcoma of an intraparotid lymph node leading to a diagnosis of HIV. Laryngoscope. 2005;115(5):861–863
  183. Lager I, Altini M, Coleman H, Ali H. Oral Kaposi’s sarcoma: a clinicopathologic study from South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(6):701–710
  184. Konstantinopoulos PA, Goldsztein H, Dezube BJ, Pantanowitz L. Acquired immunodeficiency syndrome related Kaposi’s sarcoma eroding the maxillary bone. J Laryngol Otol. 2008;122(9):993–997
  185. Caponetti G, Dezube BJ, Restrepo CS, Pantanowitz L. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer. 2007;109(6):1040–1052
  186. Lausten LL, Ferguson BL, Barker BF, Cobb CM. Oral Kaposi sarcoma associated with severe alveolar bone loss: case report and review of the literature. J Periodontol. 2003;74(11):1668–1675
  187. Castle JT, Thompson LD. Kaposi sarcoma of major salivary gland origin: a clinicopathologic series of six cases. Cancer. 2000;88(1):15–23
  188. Qunibi W, Al-Furayh O, Almeshari K, Lin SF, Sun R, Heston L, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi’s sarcoma in Saudi Arabia. Transplantation. 1998;65(4):583–585
  189. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, et al. HHV-8/KSHV during the development of Kaposi’s sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol. 2005;32(1):21–27
  190. Pyakurel P, Massambu C, Castaños-Vélez E, Ericsson S, Kaaya E, Biberfeld P, et al. Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma. J Acquir Immune Defic Syndr. 2004;36(2):678–683
  191. Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, et al. Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 2007;67(9):4042–4051
  192. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Heiden T, Biberfeld P. Lymphatic and vascular origin of Kaposi’s sarcoma spindle cells during tumor development. Int J Cancer. 2006;119(6):1262–1267
  193. Carroll PA, Brazeau E, Lagunoff M. Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004;328(1):7–18
  194. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434–440
  195. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034–4043
  196. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi’s sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. 2003;13(1):83–86
  197. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10(6):412–426
  198. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, et al. Treatments of AIDS-related Kaposi’s sarcoma. Crit Rev Oncol Hematol. 2005;53(3):253–265
  199. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. J Clin Oncol. 2004;22(3):399–402
  200. Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, et al. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94(7):1000–1006
  201. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS. 2003;17(11):F17–F22
  202. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS. 2009;23(13):1701–1706
  203. Bihl F, Mosam A, Henry LN, Chisholm JV, Dollard S, Gumbi P, et al. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS. 2007;21(10):1245–1252
  204. Sullivan RJ, Pantanowitz L, Dezube BJ. Targeted therapy for Kaposi sarcoma. BioDrugs. 2009;23(2):69–75
  205. Dezube BJ. Management of AIDS-related Kaposi’s sarcoma: advances in target discovery and treatment. Expert Rev Anticancer Ther. 2002;2(2):193–200
  206. Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. For the International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol. 2001;2(2):77–87
  207. Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, et al. Caelyx/Kaposi’s Sarcoma Spanish Group. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47(3):410–417
  208. Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG. Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol. 1993;28(1):61–65
  209. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, De la Rosa-García E, Volkow-Fernández P, Súchil-Bernal L, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002;38(5):460–467
  210. Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(5):571–578
  211. Caccialanza M, Marca S, Piccinno R, Eulisse G. Radiotherapy of classic and human immunodeficiency virus-related Kaposi’s sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol. 2008;22(3):297–302
  212. Syndikus I, Vinall A, Rogers P, Spittle M. High dose rate Microselectron moulds for Kaposi sarcoma of the palate. Radiother Oncol. 1997;42(2):167–170
  213. Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, et al. Use of antiherpes drugs and the risk of Kaposi’s sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 1996;173(6):1477–1480
  214. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS. 1996;10(10):1101–1105
  215. Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198(1):23–30
  216. Mazzi R, Parisi SG, Sarmati L, Uccella I, Nicastri E, Carolo G, et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi’s sarcoma progression in two patients with AIDS. AIDS. 2001;15(15):2061–2062
  217. Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis. 2003;187(1):149–153
  218. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol. 2008;18(5):321–329
  219. Charfi S, Krichen-Makni S, Yaich S, Makni H, Khabir A, Amouri A, et al. Successful treatment of post-renal transplant gastric and pulmonary Kaposi’s sarcoma with conversion to rapamycin treatment. Saudi J Kidney Dis Transpl. 2007;18(4):617–620
  220. Volkow P, Zinser JW, Correa-Rotter R. Molecularly targeted therapy for Kaposi’s sarcoma in a kidney transplant patient: case report, “what worked and what did not”. BMC Nephrol. 2007;8:6
  221. Dezube BJ, Sullivan R, Koon HB. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi’s sarcoma: bidirectional translational science. J Cell Physiol. 2006;209(3):659–662
  222. Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi’s sarcoma. Cancer Res. 2008;68(20):8361–8368
  223. Ahmadpoor P. Human herpesvirus-8 and kaposi sarcoma after kidney transplantation: mechanisms of tumor genesis. Iran J Kidney Dis. 2009;3(3):121–126
  224. El-Agroudy AE, El-Baz MA, Ismail AM, Ali-El-Dein B, El-Dein AB, Ghoneim MA. Clinical features and course of Kaposi’s sarcoma in Egyptian kidney transplant recipients. Am J Transplant. 2003;3(12):1595–1599
  225. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood. 2000;96(7):2562–2567
  226. Pelser C, Dazzi C, Graubard BI, Lauria C, Vitale F, Goedert JJ. Risk of classic Kaposi sarcoma with residential exposure to volcanic and related soils in Sicily. Ann Epidemiol. 2009;19(8):597–601
  227. Goedert JJ, Vitale F, Lauria C, Serraino D, Tamburini M, Montella M, et al. Classical Kaposi’s Sarcoma Working Group Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst. 2002;94(22):1712–1718
  228. Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. 2006;107(9):2282–2290

PII: S1368-8375(09)01011-2

doi: 10.1016/j.oraloncology.2009.12.006

Oral Oncology
Volume 46, Issue 3 , Pages 135-145 , March 2010

Article Tools

* Image Usage & Resolution